{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:08:07Z","timestamp":1789610887135,"version":"build-2803163510"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022817","name":"Lanzhou University Second Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360029"],"award-info":[{"award-number":["82360029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560044"],"award-info":[{"award-number":["82560044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.leukres.2026.108200","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:01:35Z","timestamp":1773457295000},"page":"108200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Diagnostic updates and research advances in AML-MR: Integrating molecular genetics and immune mechanisms"],"prefix":"10.1016","volume":"163","author":[{"given":"Nan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuxi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.leukres.2026.108200_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/fon-2019-0670","article-title":"Acute myeloid leukemia transformed to a targetable disease","volume":"16","author":"Saleh","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.leukres.2026.108200_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib3","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/bloodadvances.2024013304","article-title":"Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia","volume":"9","author":"Ruhnke","year":"2025","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.leukres.2026.108200_bib4","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","article-title":"Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting","volume":"7","author":"Attardi","year":"2023","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2026.108200_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108200_bib7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108200_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/diseases10020033","article-title":"Microenvironmental features driving immune evasion in myelodysplastic syndromes and acute myeloid leukemia","volume":"10","author":"Barakos","year":"2022","journal-title":"Diseases"},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"7749","key":"10.1016\/j.leukres.2026.108200_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.20517\/cdr.2023.39","article-title":"Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia","volume":"6","author":"Gurska","year":"2023","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","article-title":"Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia","volume":"11","author":"Yang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib14","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","article-title":"AML classification in the year 2023: how to avoid a Babylonian confusion of languages","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-024-01571-4","article-title":"A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC","volume":"17","author":"Xiao","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108200_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101156","article-title":"Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia","volume":"64","author":"Chandra","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2026.108200_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101055","article-title":"TP53 in AML and MDS: the new (old) kid on the block","volume":"60","author":"Marks","year":"2023","journal-title":"Blood Rev."},{"issue":"23","key":"10.1016\/j.leukres.2026.108200_bib19","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-026-00751-x","article-title":"Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML","volume":"15","author":"Qiu","year":"2026","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108200_bib21","article-title":"The interaction between common genetic mutations in AML and the immune landscape: mechanisms and implications for immune response","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2023011869","article-title":"A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria","volume":"8","author":"Zhou","year":"2024","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.leukres.2026.108200_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3343\/alm.2024.0194","article-title":"Reclassification of acute myeloid leukemia according to the 2022 World Health Organization classification and the international consensus classification using open-source data","volume":"45","author":"Yun","year":"2025","journal-title":"Ann. Lab Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/hematology.2022000324","article-title":"Optimizing outcomes in secondary AML","volume":"2022","author":"Matthews","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.leukres.2026.108200_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1400461","article-title":"Novel insights and therapeutic approaches in secondary AML","volume":"14","author":"Marconi","year":"2024","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2026.108200_bib26","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2016-09-738161","article-title":"Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia","volume":"129","author":"Bochtler","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108200_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2026.108200_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107546","article-title":"Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia","volume":"144","author":"Parmar","year":"2024","journal-title":"Leuk. Res."},{"issue":"19","key":"10.1016\/j.leukres.2026.108200_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180069","article-title":"Distinct landscape and clinical implications of therapy-related clonal hematopoiesis","volume":"134","author":"Takahashi","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.leukres.2026.108200_bib30","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"issue":"18","key":"10.1016\/j.leukres.2026.108200_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184576","article-title":"Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications","volume":"20","author":"Yang","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-023-00878-8","article-title":"Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm","volume":"13","author":"Tefferi","year":"2023","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ajh.27628","article-title":"Clinico-genomic interrogation of secondary-type acute myeloid leukemia: response and outcomes to contemporary therapies","volume":"100","author":"Senapati","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.leukres.2026.108200_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cbi.2009.11.025","article-title":"Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia","volume":"184","author":"Qian","year":"2010","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib36","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood-2005-09-3610","article-title":"De novo synthesis of early growth response factor-1 is required for the full responsiveness of mast cells to produce TNF and IL-13 by IgE and antigen stimulation","volume":"107","author":"Li","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2026.108200_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jlb.60.2.159","article-title":"The role of early growth response gene 1 (egr-1) in regulation of the immune response","volume":"60","author":"McMahon","year":"1996","journal-title":"J. Leukoc. Biol."},{"issue":"41","key":"10.1016\/j.leukres.2026.108200_bib38","doi-asserted-by":"crossref","first-page":"26923","DOI":"10.1074\/jbc.273.41.26923","article-title":"The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells","volume":"273","author":"Decker","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.leukres.2026.108200_bib39","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00277-022-04863-2","article-title":"Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission","volume":"101","author":"Zeng","year":"2022","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1074\/jbc.275.1.197","article-title":"Ca(2+)-dependent gene expression mediated by MEF2 transcription factors","volume":"275","author":"Blaeser","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.leukres.2026.108200_bib41","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/eji.202048869","article-title":"Nur'turing tumor T cell tolerance and exhaustion: novel function for nuclear receptor Nur77 in immunity","volume":"50","author":"Lith","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib42","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.4049\/jimmunol.0900894","article-title":"Phosphorylation of Nur77 by the MEK-ERK-RSK cascade induces mitochondrial translocation and apoptosis in T cells","volume":"183","author":"Wang","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2026.108200_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-065X.2003.00008.x","article-title":"The PI-3 kinase\/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3","volume":"192","author":"Kane","year":"2003","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clim.2009.02.009","article-title":"T-bet expression is regulated by EGR1-mediated signaling in activated T cells","volume":"131","author":"Shin","year":"2009","journal-title":"Clin. Immunol."},{"issue":"1-2","key":"10.1016\/j.leukres.2026.108200_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2013.02.001","article-title":"NAB2 and EGR-1 exert opposite roles in regulating TRAIL expression in human natural killer cells","volume":"151","author":"Balzarolo","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.leukres.2026.108200_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fcimb.2019.00349","article-title":"Sustained Egr-1 response via p38 MAP kinase signaling modulates early immune responses of dendritic cells parasitized by toxoplasma gondii","volume":"9","author":"Ten Hoeve","year":"2019","journal-title":"Front Cell Infect. Microbiol"},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/bloodadvances.2023010435","article-title":"Monosomy 7\/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia","volume":"8","author":"Eldfors","year":"2024","journal-title":"Blood Adv."},{"issue":"16","key":"10.1016\/j.leukres.2026.108200_bib48","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood-2016-10-743302","article-title":"Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms","volume":"129","author":"Tesi","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib49","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/jid.2010.387","article-title":"Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis","volume":"131","author":"Hershkovitz","year":"2011","journal-title":"J. Investig. Dermatol."},{"issue":"21","key":"10.1016\/j.leukres.2026.108200_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158869","article-title":"Mutant Samd9l expression impairs hematopoiesis and induces bone marrow failure in mice","volume":"132","author":"Abdelhamed","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib51","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ccr.2014.03.016","article-title":"MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia","volume":"25","author":"Chen","year":"2014","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.leukres.2026.108200_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162515","article-title":"Loss of Mll3 catalytic function promotes aberrant myelopoiesis","volume":"11","author":"Arcipowski","year":"2016","journal-title":"PLOS One"},{"issue":"8","key":"10.1016\/j.leukres.2026.108200_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114542","article-title":"Kmt2c restricts G-CSF-driven HSC mobilization and granulocyte production in a methyltransferase-independent manner","volume":"43","author":"Wang","year":"2024","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib54","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2012-04-426965","article-title":"CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia","volume":"121","author":"McNerney","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2026.108200_bib55","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1093\/nar\/gkx218","article-title":"The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters","volume":"45","author":"Arthur","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1016\/j.leukres.2026.108200_bib56","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc3805","article-title":"CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers","volume":"14","author":"Ramdzan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2026.108200_bib57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41388-023-02612-x","article-title":"Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells","volume":"42","author":"An","year":"2023","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.leukres.2026.108200_bib58","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.stem.2021.06.004","article-title":"Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis","volume":"28","author":"Subedi","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.leukres.2026.108200_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107500","article-title":"Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia","volume":"141","author":"Berton","year":"2024","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib60","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.7150\/ijbs.58888","article-title":"Splicing factor SRSF2-centric gene regulation","volume":"17","author":"Li","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"17","key":"10.1016\/j.leukres.2026.108200_bib61","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1007\/s00018-019-03362-4","article-title":"Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules","volume":"77","author":"Wang","year":"2020","journal-title":"Cell Mol. Life Sci."},{"issue":"51","key":"10.1016\/j.leukres.2026.108200_bib62","doi-asserted-by":"crossref","first-page":"26377","DOI":"10.1074\/jbc.M116.753046","article-title":"Serine\/arginine-rich splicing factor 2 modulates herpes simplex virus type 1 replication via regulating viral gene transcriptional activity and pre-mRNA splicing","volume":"291","author":"Wang","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.leukres.2026.108200_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109443","article-title":"Targeting SRSF2 mutations in leukemia with RKI-1447: A strategy to impair cellular division and nuclear structure","volume":"27","author":"Su","year":"2024","journal-title":"iScience"},{"issue":"18","key":"10.1016\/j.leukres.2026.108200_bib64","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1007\/s00018-020-03493-z","article-title":"The SF3b complex: splicing and beyond","volume":"77","author":"Sun","year":"2020","journal-title":"Cell Mol. Life Sci."},{"issue":"10","key":"10.1016\/j.leukres.2026.108200_bib65","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","article-title":"Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia","volume":"34","author":"Bamopoulos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2026.108200_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-020-00220-5","article-title":"The biological function and clinical significance of SF3B1 mutations in cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"Biomark. Res."},{"issue":"12","key":"10.1016\/j.leukres.2026.108200_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121844","article-title":"Mutations in splicing factor genes in myeloid malignancies: significance and impact on clinical features","volume":"11","author":"Visconte","year":"2019","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.leukres.2026.108200_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184406","article-title":"The biological and clinical consequences of RNA splicing factor U2AF1 mutation in myeloid malignancies","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib69","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish acute leukemia registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108200_bib70","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.freeradbiomed.2025.01.019","article-title":"U2AF1 mutation causes an oxidative stress and DNA repair defect in hematopoietic and leukemic cells","volume":"228","author":"Li","year":"2025","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib71","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"7367","key":"10.1016\/j.leukres.2026.108200_bib72","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.leukres.2026.108200_bib73","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib74","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41588-021-00828-9","article-title":"Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition","volume":"53","author":"Inoue","year":"2021","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.leukres.2026.108200_bib75","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.leukres.2026.108200_bib76","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","article-title":"Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias","volume":"188","author":"Kim","year":"2025","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s12185-023-03586-y","article-title":"Epigenetic regulation by ASXL1 in myeloid malignancies","volume":"117","author":"Yang","year":"2023","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-022-01336-x","article-title":"ASXL1\/2 mutations and myeloid malignancies","volume":"15","author":"Medina","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2026.108200_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2022.09.003","article-title":"Role of ASXL1 in hematopoiesis and myeloid diseases","volume":"115","author":"Gao","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2026.108200_bib80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.exphem.2020.01.002","article-title":"ASXL1 mutation in clonal hematopoiesis","volume":"83","author":"Fujino","year":"2020","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108200_bib81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12185-018-2563-7","article-title":"Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms","volume":"110","author":"Asada","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"6718","key":"10.1016\/j.leukres.2026.108200_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4492","article-title":"Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy","volume":"386","author":"Kang","year":"2024","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.leukres.2026.108200_bib83","article-title":"EZH2 mutations are related to low blast percentage in bone marrow and -7\/del(7q) in de novo acute myeloid leukemia","volume":"8","author":"Wang","year":"2013","journal-title":"PLOS One"},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071639","article-title":"EZH2 in myeloid malignancies","volume":"9","author":"Rinke","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.leukres.2026.108200_bib85","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1515\/hsz-2019-0436","article-title":"EZH2 function in immune cell development","volume":"401","author":"Nutt","year":"2020","journal-title":"Biol. Chem."},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib86","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12185-022-03466-x","article-title":"The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy","volume":"116","author":"Wang","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108200_bib87","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations (*)","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib88","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","article-title":"The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells","volume":"39","author":"Tumes","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib89","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib90","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.4049\/jimmunol.177.6.3721","article-title":"IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression","volume":"177","author":"Suto","year":"2006","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2026.108200_bib91","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.leukres.2026.108200_bib92","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1101\/gad.14.14.1810","article-title":"BCoR, a novel corepressor involved in BCL-6 repression","volume":"14","author":"Huynh","year":"2000","journal-title":"Genes Dev."},{"issue":"24","key":"10.1016\/j.leukres.2026.108200_bib93","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.2021010958","article-title":"BCOR gene alterations in hematologic diseases","volume":"138","author":"Sportoletti","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2026.108200_bib94","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/epi-2018-0195","article-title":"BCOR involvement in cancer","volume":"11","author":"Astolfi","year":"2019","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib95","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41467-019-09250-6","article-title":"Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis","volume":"10","author":"Kelly","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib96","first-page":"1779","article-title":"Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms","volume":"109","author":"Baranwal","year":"2024","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2026.108200_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092095","article-title":"Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia","volume":"13","author":"Eckardt","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.leukres.2026.108200_bib98","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241133","article-title":"BCOR and ZC3H12A suppress a core stemness program in exhausted CD8+ T cells","volume":"222","author":"Xu","year":"2025","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib99","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41388-024-03221-y","article-title":"Emerging roles of cohesin-STAG2 in cancer","volume":"44","author":"Scott","year":"2025","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.stem.2019.08.003","article-title":"Cohesin members Stag1 and Stag2 display distinct roles in chromatin accessibility and topological control of HSC self-renewal and differentiation","volume":"25","author":"Viny","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.leukres.2026.108200_bib101","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.leukres.2026.108200_bib102","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3324\/haematol.2020.248807","article-title":"Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia","volume":"106","author":"Mart\u00edn-Izquierdo","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/bloodadvances.2019000168","article-title":"An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1","volume":"4","author":"Al-Harbi","year":"2020","journal-title":"Blood Adv."},{"issue":"25","key":"10.1016\/j.leukres.2026.108200_bib104","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1182\/blood-2010-12-326710","article-title":"AML1\/RUNX1 functions as a cytoplasmic attenuator of NF-\u03baB signaling in the repression of myeloid tumors","volume":"118","author":"Nakagawa","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib105","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41590-024-01807-y","article-title":"PU.1 and BCL11B sequentially cooperate with RUNX1 to anchor mSWI\/SNF to poise the T cell effector landscape","volume":"25","author":"Gamble","year":"2024","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib106","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1038\/s41598-021-84190-0","article-title":"Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia","volume":"11","author":"Dao","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"26","key":"10.1016\/j.leukres.2026.108200_bib108","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2026.108200_bib109","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","article-title":"FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia","volume":"25","author":"Krauss","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2026.108200_bib110","doi-asserted-by":"crossref","first-page":"e1414","DOI":"10.1634\/theoncologist.2019-0785","article-title":"EMA review of daunorubicin and cytarabine encapsulated in liposomes (Vyxeos, CPX-351) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes","volume":"25","author":"Tzogani","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2026.108200_bib111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.critrevonc.2019.03.003","article-title":"Challenges in the diagnosis and treatment of secondary acute myeloid leukemia","volume":"138","author":"Ossenkoppele","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ejh.14278","article-title":"Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy","volume":"113","author":"Acker","year":"2024","journal-title":"Eur. J. Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108200_bib113","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib114","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2026.108200_bib115","first-page":"1","article-title":"Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis","author":"Huang","year":"2025","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib116","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-025-06399-7","article-title":"Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy","volume":"104","author":"Lin","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108200_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107735","article-title":"Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B\u20118800 in lower-risk myelodysplastic syndrome","volume":"156","author":"Foran","year":"2025","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.leukres.2026.108200_bib118","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2026.108200_bib119","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.leukres.2026.108200_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011222","article-title":"Investigating the molecular mechanism of H3B-8800: a splicing modulator inducing preferential lethality in spliceosome-mutant cancers","volume":"22","author":"Spinello","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"728","key":"10.1016\/j.leukres.2026.108200_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade2774","article-title":"Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML","volume":"16","author":"Wheeler","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib122","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163964","article-title":"Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models","volume":"134","author":"Ge","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib123","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2017-06-789669","article-title":"Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies","volume":"131","author":"Yang","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108200_bib124","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A phase I\/II open-label study of molibresib for the treatment of relapsed\/refractory hematologic malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2026.108200_bib125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007490","article-title":"Discovery of U2AF1 neoantigens in myeloid neoplasms","volume":"11","author":"Biernacki","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.leukres.2026.108200_bib126","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.HS9.0000843408.31385.3f","article-title":"S129: Takeaim leukemia- a phase 1\/2A study of the IRAK4 inhibitor emavusertib (CA-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed\/refractory AML or MDS","volume":"6","author":"Garcia-Manero","year":"2022","journal-title":"HemaSphere"},{"issue":"16_","key":"10.1016\/j.leukres.2026.108200_bib127","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","article-title":"Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome","volume":"40","author":"Garcia-Manero","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108200_bib128","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1016\/j.clml.2025.05.020","article-title":"Meeting report from the 2024 symposium on IRAK4 in cancer: highlights and clinical updates","volume":"25","author":"Winer","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.leukres.2026.108200_bib129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14728222.2021.1915991","article-title":"Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications","volume":"25","author":"Gonzales","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"14","key":"10.1016\/j.leukres.2026.108200_bib130","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.7150\/thno.53170","article-title":"Tanshinone I, a new EZH2 inhibitor restricts normal and malignant hematopoiesis through upregulation of MMP9 and ABCG2","volume":"11","author":"Huang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.leukres.2026.108200_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107964","article-title":"Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies","volume":"153","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.leukres.2026.108200_bib132","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2017.10.015","article-title":"Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo","volume":"413","author":"Wen","year":"2018","journal-title":"Cancer Lett."},{"issue":"31","key":"10.1016\/j.leukres.2026.108200_bib133","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108200_bib134","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2026.108200_bib135","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-25-0229","article-title":"Azacitidine, venetoclax, and magrolimab in newly diagnosed and relapsed refractory acute myeloid leukemia: phase Ib\/II study and correlative analysis","volume":"31","author":"Daver","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2026.108200_bib136","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/10428194.2022.2148212","volume":"64","author":"Assouline","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib137","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.leukres.2026.108200_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100106","article-title":"Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4(+) T cells in MDS","volume":"2","author":"Griffiths","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"16","key":"10.1016\/j.leukres.2026.108200_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.leukres.2026.108200_bib140","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/biom.13433","article-title":"Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics","volume":"78","author":"Gerard","year":"2022","journal-title":"Biometrics"},{"issue":"6","key":"10.1016\/j.leukres.2026.108200_bib141","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ajh.27647","volume":"100","author":"Esteve","year":"2025","journal-title":"Am. J. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:48:01Z","timestamp":1776131281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":141,"alternative-id":["S0145212626000445"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108200","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic updates and research advances in AML-MR: Integrating molecular genetics and immune mechanisms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108200"}}